healthcare

Hospitals Look to Raise Treatment Costs as Nurses’ Salaries Increase

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/hospitals-look-to-raise-treatment-costs-as-nurses-salaries-increase-11652007602 .

Hospitals Look to Raise Treatment Costs as Nurses’ Salaries Increase

Some hospitals grappling with rising nurses are seeking to raise prices by up to 15%, touching off contract fights with health insurers and businesses and threatening higher premiums. Neither of the chains would specify the price increases they are requesting, but people familiar with negotiations say some hospitals are asking to increase prices by 7.5% …

Hospitals Look to Raise Treatment Costs as Nurses’ Salaries Increase Read More »

FDA restricts Johnson & Johnson’s COVID-19 vaccine due to blood clot risk

WASHINGTON — US regulators on Thursday strictly limited who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots. The Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J’s JNJ, -1.91% vaccine. US authorities …

FDA restricts Johnson & Johnson’s COVID-19 vaccine due to blood clot risk Read More »

FDA Limits Authorized Use of J&J’s Covid-19 Vaccine

The Food and Drug Administration limited the use of the Covid-19 vaccine from Johnson & Johnson after reviewing the risk of life-threatening blood clots. The agency said Thursday that the J&J shot’s authorization was now only for adults for whom other shots aren’t available or medically appropriate, or who won’t take another vaccine. .

Biogen Faces Tough Rebuild After Casting Off Its Troubled Alzheimer’s Drug

Biogen Inc. must now reckon with declining sales of drugs facing heavy competition and the risky odds of finding success in its pipeline, after giving up on the Alzheimer’s therapy that was supposed to propel it to new heights but instead crashed. Adding to its challenges, the biotech will have to pull off a turnaround …

Biogen Faces Tough Rebuild After Casting Off Its Troubled Alzheimer’s Drug Read More »

Pfizer’s Covid-19 Pill Failed Study Testing Its Preventive Use

The Covid-19 pill from Pfizer Inc. failed to prevent symptomatic infections in adults who had been exposed to the pandemic virus, a late-stage study found. Pfizer said Friday that the drug, named Paxlovid, failed the study’s main objective of meaningfully reducing the risk of confirmed and symptomatic Covid-19 infections in adults who were exposed to …

Pfizer’s Covid-19 Pill Failed Study Testing Its Preventive Use Read More »

Telehealth Startup Cerebral to Stop Prescribing Adderall for New Patients

Cerebral Inc. Executives told its clinicians that the company will pause prescribing controlled substances such as Adderall to treat attention-deficit hyperactivity disorder in new patients beginning Monday, the company said. Cerebral’s co-founder and chief executive, Kyle Robertsonmade the announcement in an email sent to staff on Wednesday, adding that the company will continue to treat …

Telehealth Startup Cerebral to Stop Prescribing Adderall for New Patients Read More »

Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm Treatment

People with Alzheimer’s disease will be less likely to receive Biogen Inc.’s Aduhelm treatment because of the company’s decision to slash commercial support for the drug in the face of restricted reimbursement by the US Medicare program and other insurers. The Cambridge, Mass., company said Tuesday that it is eliminating its “commercial infrastructure” for Aduhelm. …

Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm Treatment Read More »